JUVÉDERM VOLBELLA® XC: NEW LIP FILLER APPROVED BY FDA

Juvéderm® Volbella® with Lidocaine is Allergan’s latest advancement in the Juvéderm® range of facial fillers.

Volbella has been approved for use in the lips for lip augmentation and for correction of perioral rhytids, commonly referred to as perioral lines, in adults over the age of 21.

Volbella was developed specifically for the lips and mouth area. It is a smooth gel that is injected, using an ultra-fine needle. It has been specifically developed to give a soft, natural feel.

The gel fills in lip lines and wrinkles while the hyaluronic acid within attracts and retains moisture and has been found to increase lip fullness and soften the appearance of lines around the mouth through one year.

“Many of my patients are very bothered by the lines that can appear around the lips, known as perioral rhytids. Additionally, when seeking lip augmentation, patients want a smooth, result that is not drastic” said Dr. David E. Bank, clinical trial investigator, and founder of The Center for Dermatology, Cosmetic & Laser Surgery.

“Juvéderm® Volbella® XC adds fullness to the lips and softens the appearance of the lines around the lips. With Juvéderm® Volbella® XC I am able to subtly enhance my patients’ pout,” added Dr. Bank.

“The FDA approval of Juvéderm® Volbella® XC further demonstrates Allergan’s commitment to developing advanced products and technologies that allow healthcare providers to better address evolving patient needs,” said Bill Meury, Chief Commercial Officer, Allergan.

“Additionally, this approval brings to market a product, unlike anything that is currently available in the United States. Juvéderm® Volbella® XC is formulated with VYCROSS® technology, a proprietary filter technology from Allergan, which yields smooth products that have been engineered to address specific patient concerns such as lip fullness, age-related volume loss in the cheek area, or perioral rhytids,” added Meury.

A study showed that 98 percent of people who had Juvéderm® Volbella® with Lidocaine reported that their lip appearance goals had been achieved; with results lasting up to 12 months.

Dr. Eliot Battle

CEO & Founder at Cultura Dermatology & Plastic Surgery

Dr. Eliot Battle, CEO of Cultura Dermatology, is a global leader in cosmetic dermatology and laser innovation. His Harvard research pioneered “color-blind” lasers, making treatments safe for all skin tones. A sought-after expert featured in TIME, Oprah, and The New York Times, he continues to advance inclusive, cutting-edge dermatological care.